DNA test to predict HSIL recurrence after conization
Part of Cancer, Women’s health & pregnancy clinical trials.
This study looks at a simple DNA test on your cervical cells to predict whether your condition (HSIL with positive margins) might come back after conization. This could help doctors decide if you need more treatment or just careful monitoring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 25 and 55 years old.
- You must have had your first cervical conization (a procedure that removes a cone-shaped piece of tissue from the cervix) – either cold knife or loop electrosurgical excision.
- Your post-surgery pathology must show high-grade squamous intraepithelial lesion (HSIL), also known as CIN2 or CIN3.
- The edges of the removed tissue must contain HSIL (positive margins).
- You cannot have any other cancer or precancerous condition.
- You must be willing to come back for follow-up visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether removing a small piece of the cervix (cone biopsy) can help diagnose hidden precancer when regular tests are unclear. It may help you get a clearer diagnosis if you have ongoing HPV or abnormal cell changes.
This study uses a simple blood test to look for tiny bits of cancer DNA after your treatment. It aims to see if this test can help predict whether the cancer might come back.
This study tests a light-based treatment called photodynamic therapy for cervical pre-cancer (CIN2). It may help remove abnormal cells while avoiding more invasive surgery, and aims to see if this treatment is safe and works well.
This trial studies a blood test that looks for HPV DNA after cervical cancer surgery. The test may help doctors predict if the cancer might come back and decide if more treatment is needed.
This trial compares a liquid-based cytology test with a molecular screening test to find early changes in the cervix that could lead to cancer. It may help you understand which test is better at detecting these changes before they become serious.
This trial uses a simple blood test to look for cancer DNA (ctDNA) and HPV DNA after cervical cancer surgery. The goal is to detect any return of the cancer early, so you and your doctor can act quickly.
Hear when a new High-grade Squamous Intraepithelial Lesions (HSIL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.